Results 71 to 80 of about 5,710 (181)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, Volume 15, Issue 20, 27 May 2026.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia

CJC Open, 2019
Background: Inhibitors of proprotein convertase subtilisin kexin 9 are indicated in Canada for treatment of patients with familial hypercholesterolemia (FH).
Timothy Lee, BSc, Michael A. Iacocca, MSc, Matthew R. Ban, BSc, Robert A. Hegele, MD   +3 more
doaj   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, Volume 61, Issue 3, Page 319-329, May 2026.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

Effects of Evolocumab on Carotid Intima-Media Thickness and Clinical Parameters in Patients Taking a Statin

, 2020
We determined the effects of evolocumab, a fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, on carotid intima-media thickness (IMT) and the factors associated with the change in carotid IMT in patients taking a ...
Susumu Ookawara, Aizan Hirai, Shigeki Imamura, Keiji Hirai, Yoshiyuki Morishita   +4 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Proprotein convertase subtilisin/kexin type 9 inhibitors protect against contrast-associated acute kidney injury in patients with atherosclerotic cardiovascular disease

Frontiers in Cardiovascular Medicine
Background and aimsContrast-associated acute kidney injury (CA-AKI) may occur in patients undergoing medical procedures involving x-rays and radiocontrast media, potentially resulting in prolonged renal impairment.
Yu Ma, Yu Ma, Hui Fan, Wei Mi, Jing Ma, Yong Deng, Yijie Song, Ximing Li, Ximing Li   +8 more
doaj   +1 more source

Efectividad y seguridad de evolocumab en la práctica clínica

, 2021
Resumen Introducción: Evaluar efectividad y seguridad de evolocumab en la reducción de los datos analíticos referentes al colesterol. Material y métodos: Estudio observacional, descriptivo y retrospectivo de pacientes tratados con evolocumab durante ...
Illaro Uranga,A, Gómez Gómez,D, Sánchez Gundín,J, Llorente Serrano,M, Valero Domínguez,M, Martínez Torrón,A   +5 more
core   +1 more source

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis

Frontiers in Pharmacology
ObjectiveIn December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022.
Wan Tang, Wan Tang, Wei Li, Wei Li, Anqi Zhang, Huanhuan Wu, Huanhuan Wu, Wei Lu, Wei Lu, Yan Fan, Yan Fan   +10 more
doaj   +1 more source

Profile of evolocumab and its potential in the treatment of hyperlipidemia

, 2015
Arrigo FG Cicero, Alessandro Colletti, Claudio Borghi Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy Abstract: Despite the proven efficacy of statins, they often fail to achieve low-density lipoprotein (LDL) cholesterol
Cicero AF, Borghi C, Colletti A
core  

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

, 2019
Chin-Chou Huang,1–5 Min-Ji Charng2,3 1Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; 2Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 3Faculty of Medicine, School
Huang CC, Charng MJ
core